The answer so far
In a small trial of adults with HIV and fatty liver, tesamorelin reduced a liver-fat measurement compared with placebo. A smaller biopsy analysis suggested less progression of scarring, but does not establish long-term outcomes. The US Egrifta WR label describes a different indication: excess abdominal fat in adults with HIV-associated lipodystrophy.14
On this page
- What is fatty liver, and why are there different names?
- Who took part in the tesamorelin trial?
- What did the liver-fat result mean?
- Did it prevent or reverse liver scarring?
- Is liver fat the same as visceral belly fat?
- What did the trial find about harms?
- Is tesamorelin approved for fatty liver?
- Are other liver treatments the same question?
- Sources
What is fatty liver, and why are there different names?
Fatty liver means excess fat has accumulated in the liver. It can occur with inflammation and damage, and over time some people develop fibrosis: scar tissue in the liver. The 2019 study used the name non-alcoholic fatty liver disease (NAFLD). You may also see metabolic dysfunction-associated steatotic liver disease (MASLD); the names reflect different diagnostic definitions, so they should not be assumed identical for every person.3
Who took part in the tesamorelin trial?
The researchers randomly assigned 61 adults living with HIV and measurable liver fat to tesamorelin or placebo for 12 months. Participants had specific eligibility criteria, including stable HIV treatment; people with known cirrhosis, advanced stage-4 scarring, were excluded. Fifty-four had at least one follow-up liver-fat measurement in the main analysis. Some participants stopped before the end, so missing information matters when interpreting the result. The NIH funded the study; the manufacturer supplied study drug at reduced cost, and an author disclosed company ties.1
What did the liver-fat result mean?
The main outcome was a magnetic-resonance measurement of liver fat fraction: the proportion of the measured liver signal attributed to fat. The estimated difference in change between tesamorelin and placebo favoured tesamorelin by 4.1 percentage points; the 95% confidence interval ranged from 0.7 to 7.6 points. This is a difference in a liver measurement, not 4.1% of body weight lost or proof of a cured liver.1
Did it prevent or reverse liver scarring?
A liver biopsy examines a small tissue sample. In a secondary analysis of participants with follow-up biopsies, scarring progressed in 2 of 19 in the tesamorelin group and 9 of 24 in the placebo group. That is an encouraging signal in a small, incomplete subgroup, not proof that the treatment prevents progression in everyone. The study did not find a significant improvement in existing fibrosis. It was not designed to establish fewer cases of liver failure, transplant or death.1
- 61 randomisedAdults with HIV and measured liver fat entered the placebo-controlled study.
- 54 in the main analysisParticipants with at least one follow-up liver-fat measurement; some data were missing.
- Liver-fat fractionThe estimated difference in change favoured tesamorelin by 4.1 percentage points.
- Biopsy subgroupScarring progressed in 2 of 19 versus 9 of 24; an encouraging but small, incomplete comparison.
Is liver fat the same as visceral belly fat?
No. Liver fat is inside the liver; visceral fat is stored deep in the abdomen around organs. A person can have both, but a percentage change in one is not the same measurement as a change in the other or in body weight. A separate trial tested tesamorelin for visceral fat in people with HIV-associated abdominal fat accumulation: follow those results.21
What did the trial find about harms?
Average fasting glucose and HbA1c, a longer-term blood-sugar measure, did not differ significantly between groups in this small study. However, two participants in the tesamorelin group stopped under the study protocol because of high blood sugar; some injection-site complaints were more frequent with tesamorelin. The trial was too small to rule out less common harms. The US product label includes glucose and other warnings, so an average result is not a personal safety guarantee.14
Is tesamorelin approved for fatty liver?
The US Egrifta WR label describes a specific indication: reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It does not list fatty liver as an indication and says the product is not for weight-loss management. A trial finding is not the same as a regulatory approval, and rules differ by country and product. For formulation and safety context, return to the tesamorelin profile.4
Are other liver treatments the same question?
No. In the US, Wegovy injection (semaglutide) has an accelerated approval for adults with a specific condition, noncirrhotic MASH with moderate-to-advanced fibrosis; a confirmatory clinical-outcomes trial remains ongoing. This is not approval for every form of fatty liver or a head-to-head comparison with tesamorelin. A clinician can explain what a person’s diagnosis and local options mean. For another early liver study of a different investigational molecule, see CB4211 and MOTS-c.53
Sources, kept close.
Selected supporting sources; this is not a complete literature review.
- Effects of Tesamorelin on Nonalcoholic Fatty Liver Disease in HIV: A Randomized, Double-Blind, Multicenter TrialThe Lancet HIV / PubMed Central · Randomized placebo-controlled clinical trial, 2019
- Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulationJAMA / PubMed · 2014 randomised placebo-controlled trial
- Definition and facts of NAFLD and NASHU.S. National Institute of Diabetes and Digestive and Kidney Diseases · US public-health guidance
- Egrifta WR (tesamorelin) prescribing informationU.S. National Library of Medicine / DailyMed · US product prescribing information
- Ongoing accelerated approvals for non-malignant and other indicationsU.S. Food and Drug Administration · US regulator accelerated-approval record